Neo-Adjuvant Study in Triple Negative Breast Cancer Patients

NCT01097642 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Cetuximab
DRUG: Ixabepilone

Sponsor

The Methodist Hospital Research Institute

Collaborators

[object Object]